Patents Assigned to Ogeda SA

N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Patent number: 11731974

Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.

Type: Grant

Filed: October 8, 2020

Date of Patent: August 22, 2023

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Fraser
NK-3 receptor antagonists for therapeutic treatment of leptin-related disease

Patent number: 11478472

Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.

Type: Grant

Filed: February 20, 2020

Date of Patent: October 25, 2022

Assignee: Ogeda SA

Inventors: Hamid Hoveyda, Graeme Fraser
Deuterated fezolinetant

Patent number: 11078203

Abstract: Deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl-3-(3-(methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]trizolo[4,3-a]pyrazin-7(8H)-yl)methanone: or a pharmaceutically acceptable salt or solvate thereof, as an NK-3 antagonist. Also, methods of modulating NK-3 receptor activity including administering an effective amount of the compound or pharmaceutically acceptable salt or solvate thereof. Additionally, a process for manufacturing the compound or pharmaceutically acceptable salt or solvate thereof.

Type: Grant

Filed: July 12, 2018

Date of Patent: August 3, 2021

Assignee: Ogeda SA

Inventor: Hamid Hoveyda
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

Patent number: 10941151

Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

Type: Grant

Filed: May 21, 2020

Date of Patent: March 9, 2021

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Lovat Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Patent number: 10836768

Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.

Type: Grant

Filed: November 29, 2018

Date of Patent: November 17, 2020

Assignee: Ogeda SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines

Patent number: 10787458

Abstract: Disclosed is a novel chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines of Formula (I): or a solvate thereof. The novel chiral synthesis avoids the use of protection/deprotection steps.

Type: Grant

Filed: March 22, 2019

Date of Patent: September 29, 2020

Assignee: Ogeda SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil
DEUTERATED FEZOLINETANT

Publication number: 20200270254

Abstract: Deuterated fezolinetant (R)-(4-fluorophenyl)-(8-methyl-3-(3-(methyl-d3)-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]trizolo[4,3-a]pyrazin-7(8H)-yl)methanone: or a pharmaceutically acceptable salt or solvate thereof, as an NK-3 antagonist. Also, methods of modulating NK-3 receptor activity including administering an effective amount of the compound or pharmaceutically acceptable salt or solvate thereof. Additionally, a process for manufacturing the compound or pharmaceutically acceptable salt or solvate thereof.

Type: Application

Filed: July 12, 2018

Publication date: August 27, 2020

Applicant: OGEDA SA

Inventor: Hamid HOVEYDA
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

Patent number: 10683295

Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

Type: Grant

Filed: July 27, 2018

Date of Patent: June 16, 2020

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Lovat Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat

Patent number: 10624890

Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment of pathological excess body fat and/or prevention of body fat gain in patients. Also disclosed is a cosmetic method for stimulating the loss of excess of body fat, including the administration of a NK-3 receptor antagonist.

Type: Grant

Filed: March 16, 2016

Date of Patent: April 21, 2020

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Graeme Fraser
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

Patent number: 10544150

Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

Type: Grant

Filed: February 27, 2018

Date of Patent: January 28, 2020

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme Lovat Fraser, Guillaume Dutheuil
N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

Patent number: 10214533

Abstract: Novel compounds of Formula I and their use in therapeutic treatments.

Type: Grant

Filed: April 18, 2018

Date of Patent: February 26, 2019

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Patent number: 10183948

Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.

Type: Grant

Filed: October 27, 2017

Date of Patent: January 22, 2019

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

Patent number: 10065960

Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

Type: Grant

Filed: July 14, 2015

Date of Patent: September 4, 2018

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil
Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof

Patent number: 10065961

Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

Type: Grant

Filed: September 8, 2016

Date of Patent: September 4, 2018

Assignee: Ogeda SA.

Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme L. Fraser, Marie-Odile Roy, Mohamed E. Bousmaqui, Frederic Batt
Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Patent number: 10030025

Abstract: Novel compounds of Formula I and their use in therapeutic treatments.

Type: Grant

Filed: July 8, 2016

Date of Patent: July 24, 2018

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
Substituted pyrrolidines as G-protein coupled receptor 43 agonists

Patent number: 10017468

Abstract: The present invention is directed to a process for the preparation of aryl-pyrrolidine carboxylic acid derivative compounds which are useful in treating metabolic diseases, said process consisting of coupling an aryl-pyrrolidine compound with an aryl carboxylic acid compound followed by alkaline or acidic treatment, hydrogenolysis or treatment with a fluoride of the ester intermediate to afford novel aryl-pyrrolidine carboxylic acid derivative compounds.

Type: Grant

Filed: June 15, 2017

Date of Patent: July 10, 2018

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Didier Schils, Ludivine Zoute, Julien Parcq
N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Patent number: 9987274

Abstract: A method for treating and/or preventing hot flashes, by administering, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.

Type: Grant

Filed: December 7, 2016

Date of Patent: June 5, 2018

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

Patent number: 9969738

Abstract: Novel compounds of Formula I and their use in therapeutic treatments.

Type: Grant

Filed: March 28, 2014

Date of Patent: May 15, 2018

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders

Patent number: 9969745

Abstract: Novel compounds of Formula I methods of manufacturing the compounds and their use in therapeutic treatments are presented.

Type: Grant

Filed: November 9, 2017

Date of Patent: May 15, 2018

Assignee: OGEDA SA

Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders

Patent number: 9926325

Abstract: The present invention is directed to novel compounds of formula I and their use as therapeutic compounds.

Type: Grant

Filed: August 29, 2014

Date of Patent: March 27, 2018

Assignee: Ogeda SA

Inventors: Hamid R. Hoveyda, Marie-Odile Roy, Graeme L. Fraser, Guillaume Dutheuil

1 2 next